Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 26:ciac416. doi: 10.1093/cid/ciac416

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.

This work is written by (a) US Government employee(s) and is in the public domain in the US.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 4. — Multivariable linear regression of clinical variables associated with neutralizing antibody response. Summary plot (top) showing variables retained in the stepwise regression with corresponding significant P values. Nonsignificance denoted by “ns”, P value between .10 and .05 denoted by †. P value between .05 and .01 denoted by ∗. P value between .01 and .001 denoted by ∗∗. P value less than .001 denoted by ∗∗∗. Log₂FC = log normalized fold-change over prevaccination IC50. Forest plots showing multivariable linear regression variables of response at 1, 6, 10, and 12 months following administration of second dose. Variables not reaching significance not shown in the figure are sex, race, chronic heart disease, lung disease, liver disease, current steroid use, cerebrovascular disease, HIV-Transplant-Rheum, and dementia. Intercept represents baseline comparison values: age less than 65 years, GFR greater than 60 mL/min/1.73 m², no steroid use, and no comorbidities. The 10-month time point was 1 month after the third dose. The 12-month timepoint was 3 months after the third dose. GFR, glomerular filtration rate; IC50, half maximal inhibitory concentration.